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Intralesional Macular Atrophy in
AntieVascular Endothelial Growth Factor
Therapy for Age-Related Macular
Degeneration in the IVAN Trial
Clare Bailey, MD, FRCOphth,1 Lauren J. Scott, MSc,2 Chris A. Rogers, PhD,2 Barnaby C. Reeves, MSc, DPhil,2
Barbra Hamill, BSc Hons,3 Tunde Peto, FRCOphth,4 Usha Chakravarthy, PhD, FRCOphth,4,5
Simon P. Harding, FRCOphth, MD,6 writing committee for the IVAN Study Group
Purpose: To report on the development and progression of macular atrophy (MA) and its relationship with
morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth
factor (VEGF) in Age-related Choroidal Neovascularisation trial.
Design: Reading center analysis of data from a randomized controlled trial.
Participants: Participants with previously untreated neovascular age-related macular degeneration (nAMD)
in the study eye.
Methods: Color, ﬂuorescein angiography (FA) and OCT images acquired at baseline and during the 2-year
follow-up were graded systematically for presence of MA. Regression models were constructed to explore re-
lationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity,
reading speed and index, contrast sensitivity).
Main Outcome Measures: Primary outcome was development of intralesional MA (175 mm greatest linear
dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the
neovascular lesion.
Results: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at
baseline. Incident intralesional MA occurred in 24.4% by the ﬁnal visit and extralesional MA in only 1.54%. In
fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional
MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by ﬁnal
visit were lower in study eyes that had 50% classic CNV at baseline (odds ratio [OR], 0.39; 95% conﬁdence
interval [CI], 0.19e0.80; P ¼ 0.010), subretinal ﬂuid at ﬁnal visit (OR, 0.41; 95% CI, 0.25e0.76; P ¼ 0.004), or
pigment epithelial detachment at ﬁnal visit (OR, 0.40; 95% CI, 0.21e0.74; P ¼ 0.004). Secondary analyses of
incident or progressed intralesional MA in study eyes supported these ﬁndings, with odds increasing if the fellow
eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09e5.44; P ¼ 0.030). No signiﬁcant associations were
observed between development of intralesional MA and any other morphologic or visual function measure.
Conclusions: Macular atrophy frequently develops within an nAMD lesion in eyes receiving antieVEGF
therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function
were detected, providing some reassurance to clinicians; however, the longer-term effects remain
unknown. Ophthalmology 2018;-:1e12 ª 2018 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.The treatment of neovascular age-relatedmacular degeneration
(nAMD) has been transformed by the introduction of intra-
ocular therapies that inhibit vascular endothelial growth factor
(VEGF). As increasing numbers of anti-VEGF injections are
delivered over longer periods in clinical care for nAMD, there
is much interest in potential ocular adverse effects.
The Inhibition of VEGF in Age-Related Choroidal Neo-
vascularisation (IVAN) trial1,2 compared 2 anti-VEGF agents
and 2 regimens in previously untreated eyes with nAMD in aª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.2-way factorial randomized trial. The IVAN trial reported
higher proportions of geographic atrophy (GA) in eyes allo-
cated to the continuous regimen (median, 23 injections)
compared with the discontinuous regimen (median, 13 in-
jections; odds ratio [OR], 1.47; P¼ 0.03). No difference was
detected between the 2 drugs with respect to the proportion of
eyes with GA at 2 years. Similar ﬁndings were reported in the
Comparison of Age-Related Macular Degeneration Treat-
ments Trials (CATT)3e6 and conﬁrmed in meta-analyses by1https://doi.org/10.1016/j.ophtha.2018.07.013
ISSN 0161-6420/18
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overexposure to anti-VEGF agents could cause atrophy in
the macula, contributing to poor visual outcome. Alterna-
tively, the neovascular process itself could create the condi-
tions for atrophy. Unfortunately, these and other studies have
reported on atrophy within the macula without characterizing
the location of the atrophic region with respect to the neo-
vascular lesion.
We conducted a revised grading of the image repository
in the IVAN trial to explore the effect of clinical and
morphologic predictors on the development and extent of
macular atrophy (MA) in study eyes. We carefully deﬁned
the location of MA and studied it in relation to the lesion
footprint, a topic that to date has not been studied. Addi-
tionally, we reviewed fellow eyes with lesions at baseline
for comparison with development of intralesional MA in
eyes with untreated lesions.
Methods
Full details of the data collection in IVAN are available elsewhere.7
Of particular relevance to the analysis presented herein, measures
of visual function were performed by trained and accredited
observers using a full refraction protocol, standardized charts,
and illumination comprising distance best-corrected visual acuity
(BCVA) recorded as letters read on an Early Treatment Diabetic
Retinopathy Study chart at 1 m, contrast sensitivity (CS) as letters
read at 1 m on a Pelli Robson chart, near VA measured in loga-
rithm of the minimum angle of resolution units using the Bailey
Lovie near chart at 25 cm, Belfast reading speed at 25 cm, and
reading index calculated as a function of print size.8 OCT images
were captured using Stratus (Carl Zeiss AG, Oberkocken,
Germany) or Spectralis (Heidelberg Engineering, Heidelberg,
Germany) platforms. Institutional review board or ethics
committee approval was obtained (identiﬁer, 07/NIR03/37), the
trial was registered (identiﬁer, ISRCTN92166560), and all
participants gave informed consent.
Grading
Retinal images were graded systematically by trained and
accredited graders in the Network of Reading Centres UK against a
revised protocol developed speciﬁcally for this study. The border
of the active neovascular complex (classic and occult choroidal
neovascularization, retinal angiomatous proliferation, associated
elevated blocked ﬂuorescence) was outlined at baseline, inter-
vening, and ﬁnal visits and the maximum lesion footprint was
determined.
We deﬁned MA as the presence of any of the following features
on multimodal imaging:21. Color: an area of pallor with 2 of the following: clearly
deﬁned margins, scalloped margins, identiﬁable large
choroidal vessels.
2. Fluorescein angiography (FA): area of hyperﬂuorescence
that persisted throughout the run (sometimes fading in the
late phase) with identiﬁable large choroidal vessels.
3. OCT: increased transmission of the light signal into the
choroid and thinning or absence of the outer retinal layers.
On higher-quality or higher-resolution scans, the following
additional features of MA could be used: dipping of the
photoreceptor nuclear layer toward the retinal pigment
epithelium (RPE)eBruch’s membrane complex, absence
of photoreceptor inner and outer segments, thinning ofRPEeBruch’s complex, and absence of the choriocapillaris
proﬁle.Macular atrophy was identiﬁed, segmented, and measured on FA
images (or color where FAwas not available) in 7 of 596 eyes (1.2%)
at baseline and in 103 of 596 (17.3%) at the ﬁnal visit and was
considered present if the combined greatest linear dimension of the
delineated area was 175 mm or more. The footprint of the neo-
vascular lesion was outlined on the FA at the 3 visits where this was
captured (baseline, month 12, and month 24). OCT features were
used to aid in identiﬁcation of MA; if seen on OCT but not other
modalities images were reviewed at arbitration where a senior
clinician (including U.C., T.P.) decided if atrophy was present and
localized it to the en face FA image. Graders speciﬁed the location of
MA as within (intralesional) based on the maximum lesion footprint.
Macular atrophy outside the lesion boundary was considered intra-
lesional if it was contiguous. The Wisconsin Age-related Macul-
opathy Grading System deﬁnition of GA9 was used only for
extralesional MA in addition to the greatest linear dimension
criterion, that is, at least 2 of the following: visibility of choroidal
vessels, well-deﬁned margins, and scalloped edges. All lesion area
measurements were in square millimeters, and the presence of other
FA and OCT measures was recorded. Baseline hemorrhage was
assessed on color images, and subretinal ﬂuid (SRF) and pigment
epithelial detachment (PED) were assessed on OCT. Examples from
the IVAN study showing intralesional MA within the maximum
footprint of the active neovascular complex are shown for progres-
sion and development in Figures 1 and 2, respectively, with 1
additional example for each in Supplemental Figures S1 and S2
(available at www.aaojournal.org).
Analysis
Eyes were classiﬁed by the presence of intralesional MA as fol-
lows: no intralesional MA at baseline or ﬁnal visit, intralesional
MA developed between baseline and ﬁnal visit, or intralesional
MA present at both visits. For fellow eyes, which could have
received no previous treatment or could have received previous
verteporﬁn photodynamic, anti-VEGF therapy, or both, the pres-
ence or absence of an nAMD lesion at baseline was determined.
The analysis did not include the 19 study eyes that showed GA
(extralesional MA) only at baseline and 3 that showed none at
baseline and GA only at follow-up, nor the 14 fellow eyes that
showed GA only at baseline and the 5 eyes that showed none at
baseline and GA only at follow-up.
The primary outcome was deﬁned as incident intralesional MA.
Deﬁning the primary outcome as incident intralesional MA meant
that the primary analysis excluded study eyes with intralesional
atrophy at baseline. In a secondary analysis, eyes with intralesional
MA at baseline were divided according to whether the area of
intralesional MA had increased by 20% or more between visits,
denoting progression, or not (see Supplemental Methods, available
at www.aaojournal.org). This cutoff point was chosen because the
proportion classiﬁed as progressing did not vary when the cutoff
point was changed to a 50% or more. Other secondary outcomes
included area of intralesional MA (in square millimeters), distance
and near BCVA, near VA, CS, reading speed and reading index.
We deﬁned a secondary outcome of incident or progressed
intralesional MA so we could add in study eyes with intralesional
MA at baseline and investigate relationships with MA progression.
As well as testing the generalizability of the primary outcome re-
lationships, this analysis also had more statistical power.
Demographics, treatment groups, morphologic features, and
visual function measures were summarized by lesion atrophy sta-
tus. Linear regression was used to analyze the effect of study eye
lesion development on visual function metrics at the ﬁnal visit;
Figure 1. Example of a case of progression of intralesional macular atrophy (MA) with clean and annotated images. Left column, Baseline lesion shows
ﬁbrovascular pigment epithelial detachment (FPED, type 1 lesion)with a small zone ofMA.Right column, By the ﬁnal visit (24months), the zone of intralesional
MA has expanded at the site of partial involution of the FPED and a new zone of geographic atrophy (extralesional MA) has developed. Note that the lesion
footprint and features were segmented andmeasured from FA images. The color annotations are to aid interpretation. Blue line¼ total lesion footprint at baseline;
green line ¼ intralesional MA; yellow line ¼ extralesional MA; red broken line ¼ maximum lesion footprint; white arrows ¼ boundaries of MA on OCT.
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Figure 2. Example of a case of development of intralesional macular atrophy (MA) with clean and annotated images. Left column, Baseline lesion shows
classic no occult (type 2) lesion. Right column, By the ﬁnal visit (24 months), the lesion has increased slightly and involuted and a zone of intralesional MA
has developed. Note that the lesion footprint and features were segmented and measured from FA images. The color annotations are to aid interpretation.
Blue line ¼ total lesion footprint at baseline; green line ¼ intralesional MA; red broken line ¼ maximum lesion footprint; white arrows ¼ boundaries of MA
on OCT.
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Table 1. Macular Atrophy Status at Baseline and Final Visit for
Study Eyes and Fellow Eyes with a Neovascular Age-Related
Macular Degeneration Lesion at Baseline
Baseline
Final Visit
TotalNone Extralesional Intralesional Both
Study eyes
None 390 3 122 5 520
Extralesional 0 11 0 8 19
Intralesional 0 0 56 1 57
Total 390 14 178 14 596
Fellow eyes with a lesion at baseline
None 159 5 24 1 189
Extralesional 0 10 0 4 14
Intralesional 0 0 40 2 42
Both 0 0 0 3 3
Total 159 15 64 10 248
Table 2. Demographic Features, Treatment, and Key Lesion-Related R
No Intralesional Macular
Atrophy at Baseline or Final
Visit (n [ 390)
No Intralesion
Atrophy
Baseline; Dev
Final Visit (n
No. % No.
Demographic features
Age (yrs) Mean, 77.0 SD, 7.6 Mean, 78.7
Gender 163/390 41.8 49/127
Drug and treatment frequency
Bevacizumab 188/390 48 59/127
Treatment frequency Median, 19 IQR, 12e23 Median, 19 IQ
3 injections 14/390 3.6 8/127
Lesion metrics
Area of baseline
intralesional MA
(mm2)
Area of ﬁnal visit
intralesional MA
(mm2)
Median, 1.3 IQ
Area of intralesional MA
increased by 20%
SRF at baseline 301/355 84.8 97/117
SRF at ﬁnal visit 146/369 39.6 20/122
PED at baseline 269/357 75.4 99/119
PED at ﬁnal visit 323/373 86.6 91/123
Hemorrhage at baseline 223/384 58.1 83/125
Baseline CNV
Occult (<50% of lesion
area classic)
264/372 71.0 106/124
Classic (>50% of lesion
area classic)
108/372 29.0 18/124
Fellow eye
Baseline intralesional MA
No lesion 224/387 57.9 76/126
Lesion with no MA 144/387 37.2 36/126
Lesion with MA 19/387 4.9 14/126
Baseline atrophy outside
the lesion
21/387 5.4 26/126
CNV ¼ choroidal neovascularization; IQR ¼ interquartile range; MA ¼ macula
SRF ¼ subretinal ﬂuid.
Missing data as follows, number of patients (no lesion atrophy at baseline or ﬁnal
and ﬁnal visit): baseline area of atrophy, 1 (d, d, 1); ﬁnal visit area of atroph
Bailey et al  Macular Atrophy in Treated Neovascular AMDthese analyses were adjusted for baseline visual function and
included only eyes for which data for all model covariates were
available. The effect of demographic, study, and morphologic
characteristics on development of intralesional MA in both eyes
was assessed using logistic regression, and the effect of these
factors on the area of intralesional MA in the study eye was
assessed using linear regression. Treatment frequency was ﬁtted as
a continuous predictor and was presented as the effect of 3 in-
jections, that is, 1 treatment cycle.Results
All 610 patients recruited to the IVAN trial were considered for
inclusion. Data onGAor intralesionalMAweremissing for 14 study
eyes that were excluded, leaving 596 for the analyses. Table 1 shows
the atrophy status for study and fellow eyes at baseline and ﬁnal
visits; 514 ﬁnal visits (86%) were at month 24. At baseline,isk Factors by Study Eye Status for Intralesional Macular Atrophy
al Macular
at
eloped by
[ 127)
Intralesional Macular Atrophy
at Baseline and Final
Visit (n [ 57) Overall (n [ 574)
% No. % No. %
SD, 6.7 Mean, 78.7 SD, 7.6 Mean, 77.5 SD, 7.5
38.6 20/57 35.1 232/574 40.4
46 32/57 56 279/574 49
R, 11e23 Median, 21 IQR, 13e23 Median, 19 IQR, 12e23
6.3 1/57 1.8 23/574 4.0
Median, 0.7 IQR, 0.3e2.2 Median, 0.7 IQR, 0.3e2.2
R, 0.6e4.5 Median, 3.1 IQR, 1.3e4.8 Median, 2.0 IQR, 0.7e4.7
36/56 64.3 36/56 64.3
82.9 32/50 64.0 430/522 82.4
16.4 7/55 12.7 173/546 31.7
83.2 41/50 82.0 409/526 77.8
74.0 41/56 73.2 455/552 82.4
66.4 37/57 64.9 343/566 60.6
85.5 47/52 90.4 417/548 76.1
14.5 5/52 9.6 131/548 23.9
60.3 28/57 49.1 328/570 57.5
28.6 19/57 33.3 199/570 34.9
11.1 10/57 17.5 43/570 7.5
20.6 13/57 22.8 60/570 10.5
r atrophy; PED ¼ pigment epithelial detachment; SD ¼ standard deviation;
visit, lesion atrophy at ﬁnal visit but not baseline, lesion atrophy at baseline
y, 1 (d, 0, 1).
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Table 3. Clinical Measures of Vision in the Study Eye by Presence or Absence of Intralesional Macular Atrophy at Baseline and Final Visit
No Intralesional Macular Atrophy
at Baseline or Final
Visit (n [ 390)
No Intralesional
Macular Atrophy
at Baseline; Developed by
Final Visit (n [ 127)
Intralesional Macular Atrophy
at Baseline and
Final Visit (n [ 57) Overall (n [ 574)
Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range
Baseline
BCVA 66 54e74 61 50e69 64 55e73 65 52e73
Near VA 0.6 0.4e0.8 0.7 0.5e0.9 0.6 0.4e0.8 0.6 0.4e0.9
CS letters 28 23e31 28 23e30 26 23e29 28 23e30
Reading speed 46.9 31.1e63.2 41.7 24.0e59.0 39.5 26.0e55.4 44.7 29.6e61.0
Reading index 39.7 16.7e78.3 28.3 11.0e45.6 42.1 19.2e64.0 37.3 14.9e69.9
Vision too poor to read* n ¼ 3 0.8% n ¼ 0 0.0% n ¼ 2 3.6% n ¼ 5 0.9%
Final visit
BCVA 73 59e80 68 53e78 69 50e79 72 56e80
Near VA 0.4 0.3e0.7 0.5 0.3e1.0 0.5 0.3e0.9 0.4 0.3e0.7
CS letters 30 26e32 29 25e32 28 24e32 29 25e32
Reading speed 44.7 25.5e66.8 35.6 18.5e52.7 33.9 19.7e54.5 42.0 23.4e62.1
Reading index 59.9 23.4e95.2 39.2 8.6e64.1 40.3 11.4e81.4 52.1 15.6e92.3
Vision too poor to read* n ¼ 7 2.1% n ¼ 3 2.7% n ¼ 1 2.0% n ¼ 11 2.2%
Change from baseline
BCVA 5 e2 to 12 6 0e14 2 e6 to 11 5 e2 to 12
Near VA e0.1 e0.3 to 0.1 e0.1 e0.3 to 0.1 e0.1 e0.2 to 0.3 e0.1 e0.3 to 0.1
CS letters 1 e1 to 5 1 e2 to 5 0 e2 to 5 1 e2 to 5
Reading speed e2.3 e20.5 to 11.7 e4.0 e20.3 to 10.4 e4.9 e24.0 to 9.9 e3.0 e20.5 to 10.8
Reading index 5.3 e11.6 to 38.1 3.2 e11.9 to 29.0 e1.0 e25.3 to 23.9 3.9 e12.3 to 36.1
Vision too poor to read* n ¼ 10 3.0% n ¼ 3 2.8% n ¼ 3 6.0% n ¼ 16 3.3%
BCVA ¼ best-corrected visual acuity; CS ¼ contrast sensitivity; VA ¼ visual acuity.
Missing data as follows, patients (no lesion atrophy at baseline or ﬁnal visit, lesion atrophy at ﬁnal visit but not baseline, lesion atrophy at baseline and ﬁnal
visit): baseline near VA, 4 (3, 0, 1); baseline reading speed, 30 (21, 5, 4); baseline reading index, 30 (21, 5, 4); ﬁnal visit BCVA, 1 (1, 0, 0); ﬁnal visit near
VA, 55 (37, 13, 5); ﬁnal visit CS letters, 47 (30, 13, 4); ﬁnal visit reading speed, 81 (56, 18, 7); ﬁnal visit reading index, 81 (56, 18, 7); change from baseline
BCVA, 1 (1, 0, 0); change from baseline near VA, 57 (38, 13, 6); change from baseline CS letters, 47 (30, 13, 4); change from baseline reading speed, 100
(68, 22, 10).
*Vision classed as too poor to read if near VA ¼ 1.6.
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none showed both. By the ﬁnal visit, 25.0% of study eyes (130/
520) that were free of atrophy at baseline demonstrated new MA:
3 cases were extralesional, 122 cases were intralesional, and 5
cases were both. The remaining study eyes that showed no atrophy
at baseline also were free of atrophy at the ﬁnal visit (n ¼ 390).
Over the course of the trial, the overall frequency of intralesional
MA rose from 9.6% (57/596) to 32.2% (192/596).
Neovascular age-related macular degeneration lesions were
present at baseline in 42.0% of fellow eyes (248/591); this
information was missing for 5 patients. Of the 248 eyes, 42 eyes
showed intralesional MA only, 14 eyes showed extralesional MA
only, and 3 eyes showed both. By the ﬁnal visit, 30 fellow eyes
demonstrated new MA: 5 cases were extralesional, 24 cases
intralesional, and 1 case was both. The frequency of intralesional
MA in fellow eyes with a neovascular lesion at baseline rose from
16.9% (42/248) to 25.8% (64/248). Patient demographic features,
drug and treatment frequency, and key lesion metrics by study eye
intralesional MA status are shown in Table 2. Functional metrics
by study eye intralesional MA status are shown in Table 3.
Images from all 3 methods were available for 545 of 596 study
eyes (91%) at baseline and for 477 of 596 study eyes (80%) at follow-
up. At baseline, 589 eyes (99%) had undergone FA, 590 eyes (99%)
had undergone color, and 551 eyes (92%) had undergone OCT. At
follow-up, 493 eyes (83%) had undergone FA, 590 eyes (99%) had
undergone color, and 576 eyes (97%) had undergone OCT.6Primary Outcome
Figure 3 shows the relationship between several patient-, eye-, and
treatment-related predictors and the development of incident
intralesional MA in study eyes with no intralesional MA at base-
line. There was no statistically signiﬁcant difference in the odds of
incident intralesional MA between eyes treated with bevacizumab
compared with those treated with ranibizumab (OR, 0.995; 95%
conﬁdence interval [CI], 0.81e1.63; P ¼ 0.98); the number of
cycles of treatment (closely related to discontinuous vs. continuous
allocation in the IVAN trial) also had no effect (OR, 1.01 per
treatment cycle; 95% CI, 0.91e1.13 per treatment cycle;
P ¼ 0.83). The presence of SRF, PED, and hemorrhage at baseline
also were not related to the odds of incident intralesional MA.
In study eyes in which classic CNV accounted for more than
50% of the lesion area at baseline, the odds of intralesional MA
developing by the ﬁnal visit were reduced signiﬁcantly compared
with eyes in which classic CNV accounted for 50% or less of the
lesion area at baseline (OR, 0.39; 95% CI, 0.19e0.80; P ¼ 0.010).
The presence of SRF at the ﬁnal visit and PED at the ﬁnal visit (but
not at baseline) independently reduced the odds of intralesional
MA developing (OR, 0.41; 95% CI, 0.23e0.76; and OR, 0.40;
95% CI, 0.21e0.74, respectively; P ¼ 0.004 for both). The pres-
ence of intralesional MA or extralesional MA (atrophy outside the
lesion) in the fellow eye at baseline both independently increased
the odds of incident intralesional MA in the study eye (OR, 2.34;
Figure 3. Graph showing the relationship between risk factors and the development of intralesional macular atrophy (MA). The model included 425 study
eyes with no intralesional MA at baseline, all with no missing data, of whom 106 demonstrated intralesional MA by the ﬁnal visit. Treatment cycles (1
cycle ¼ 3 injections) separate continuous from discontinuous regimens. CNV ¼ choroidal neovascularization; PED ¼ pigment epithelial detachment;
SRF ¼ subretinal ﬂuid.
Bailey et al  Macular Atrophy in Treated Neovascular AMD95% CI, 0.94e5.79; P ¼ 0.07; and OR, 4.96; 95% CI,
2.34e10.51; P < 0.001, respectively).
Figure 4 shows the same analysis of factors for intralesional
MA in study eyes (Fig 3), but for the secondary outcome, that is,
incident or progressed intralesional MA. Including more study
eyes improved the precision of the effect estimates. The pattern
of the results was very similar: odds ratios were 0.31 for 50% or
less classic CNV at baseline, 0.36 for presence of SRF at ﬁnal
visit, 0.45 for presence of PED at ﬁnal visit, 2.43 for presence of
intralesional MA in the fellow eye at baseline, and 5.27 for
atrophy outside the lesion in the fellow eye at baseline.
Figure S3 (available at www.aaojournal.org) shows the analysis
of the effects of the same factors, but on the secondary outcome of
intralesional MA area. This analysis supported the negative
association between SRF and intralesional MA at the ﬁnal visit;
the area of intralesional MA was approximately one third less
when SRF was present compared with when absent (geometric
mean ratio, 0.66; 95% CI, 0.35e1.24; P ¼ 0.198). Finally, the
total area of intralesional MA was signiﬁcantly larger in patients
with intralesional MA at baseline in the fellow eye (geometric
mean ratio, 3.07; 95% CI, 1.54e6.11; P ¼ 0.002).
With respect to differences in visual function secondary out-
comes (Table 3), among study eyes free of lesion atrophy at
baseline, there were no statistically signiﬁcant differences
between eyes in which MA developed during the study and eyes
in which it did not: ﬁnal visit BCVA (e0.72 letters; 95% CI,
e3.58 to 2.40 letters; P ¼ 0.62), near VA (0.066; 95% CI,
e0.004 to e0.136; P ¼ 0.07), CS (e0.24 units; 95% CI, e1.29
to 0.80 units; P ¼ 0.65), reading speed (e3.86 units; 95% CI,
e8.94 to 1.21 units; P ¼ 0.14), or reading index (e4.46; 95%
CI, e13.66 to 4.73; P ¼ 0.34). Although the difference in meannear VA at ﬁnal visit between the 2 groups reached borderline
statistical signiﬁcance, there was no indication of any difference
in medians, and we suspect this difference arises because of
outliers.
Figure 5 shows the relationship between a subset of the factors
studied (only those available, and relevant to fellow eyes) and
incident intralesional MA in 184 fellow eyes with nAMD lesions
present at baseline and no intralesional MA (Table 4). Data were
excluded for 5 patients who showed extralesional MA only at
follow-up. The presence of intralesional MA at baseline in the
study eye was associated with increased odds of incident intrale-
sional MA in the fellow eye (OR, 3.35; 95% CI, 1.04e10.77; P ¼
0.04). Age, gender, and study eye treatment did not signiﬁcantly
affect development of incident intralesional MA in the fellow eye.Discussion
We report the ﬁndings of a detailed analysis of the clinical
and imaging dataset collected during the IVAN trial. Mac-
ular atrophy within the lesion develops or progresses in just
less than one third of eyes being treated with intravitreal
anti-VEGF therapy and occurred at a higher frequency than
might be expected from natural history. However, prevalent
and incident intralesional MA did not result in a signiﬁ-
cantly greater reduction in measures of visual function
during the study. There was no evidence to suggest that trial
allocation to drug or treatment frequency affected the inci-
dence of intralesional MA.7
Figure 4. Graph showing the relationship between risk factors and incident or progressed intralesional macular atrophy (MA) in study eyes. The reference
group was eyes with no intralesional MA combined with those in which intralesional MA did not increase by ﬁnal visit (n ¼ 319 þ 13). The comparator
group was study eyes with incident or progressed intralesional MA at the ﬁnal visit (n ¼ 106 þ 29). Treatment cycles (1 cycle ¼ 3 injections) separate
continuous from discontinuous regimens. CNV ¼ choroidal neovascularization; PED ¼ pigment epithelial detachment; SRF ¼ subretinal ﬂuid.
Figure 5. Graph showing the model exploring risk factor associations in the development of intralesional macular atrophy (MA) in 184 fellow eyes with
neovascular lesions with no missing data; 25 fellow eyes were classiﬁed as demonstrating MA by ﬁnal visit. Treatment cycles (1 cycle ¼ 3 injections) separate
continuous from discontinuous regimens.
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Table 4. Clinical Measures of Vision in the Fellow Eye by Presence or Absence of Intralesional Macular Atrophy at Baseline and Final Visit
Fellow Eye Free
of Neovascular
Age-Related Macular
Degeneration (n [ 343)
Neovascular Lesion
Present, No Atrophy
at Baseline or
Final Visit (n [ 159)
Neovascular Lesion Present,
No Atrophy at Baseline;
Developed by Final
Visit (n [ 25)
Neovascular Lesion
Present, Atrophy at
Baseline and Final
Visit (n [ 45) Overall (n [ 572)
Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range
Baseline
BCVA 81 74e85 59 19e73 55 40e76 41 17e68 75 59e84
Near VA 0.3 0.2e0.4 0.6 0.3e1.2 0.6 0.3e1.0 0.9 0.5e1.4 0.3 0.2e0.6
CS letters 32 29e35 25 11e30 27 23e29 23 7e27 30 25e34
Reading speed 60.0 45.0e75.0 47.7 28.0e63.2 42.0 25.7e62.1 37.6 14.2e52.5 54.5 38.2e70.6
Vision too poor to
read* (n, %)
n ¼ 1 0.3% n ¼ 12 9.5% n ¼ 0 0.0% n ¼ 4 12.5% n ¼ 17 3.3%
Area of intralesional
MA (mm2)
3.8 1.4e9.9 3.8 1.4e9.9
Final visit
BCVA 81 74e86 51 17e73 57 33e72 35 15e59 75 53e83
Near VA 0.3 0.2e0.4 0.6 0.3e1.3 0.7 0.5e1.4 1.0 0.5e1.5 0.3 0.2e0.7
CS letters 31 28e35 24 13e30 26 21e30 22 9e29 30 24e34
Reading speed 55.4 36.5e73.5 32.2 17.5e57.6 33.8 21.5e43.0 29.0 13.0e48.9 48.3 28.9e69.2
Vision too poor to
read* (n, %)
n ¼ 3 1.0% n ¼ 10 9.1% n ¼ 3 13.0% n ¼ 6 18.2% n ¼ 22 4.7%
Area of intralesional
MA (mm2)
1.9 1.0e4.2 4.4 1.8e9.7 3.5 1.1e8.7
Area increased
by 20%
16/40 40% 16/40 40%
BCVA ¼ best-corrected visual acuity; CS ¼ contrast sensitivity; MA ¼ macular atrophy; VA ¼ visual acuity.
Missing data as follows, number of patients (no baseline lesion, no atrophy at baseline or ﬁnal visit, atrophy at ﬁnal visit but not baseline, atrophy at baseline
and ﬁnal visit): baseline BCVA, 11 (1, 5, 2, 3); baseline near VA, 46 (6, 27, 2, 11); baseline CS letters, 11 (3, 4, 2, 2); baseline reading speed, 79 (14, 45, 3,
17); baseline area of intralesional MA, 4 (d,d,d, 4); ﬁnal visit BCVA, 42 (24, 14, 1, 3); ﬁnal visit near VA, 96 (35, 48, 2, 11); ﬁnal visit CS letters, 64
(39, 27, 1, 6); ﬁnal visit reading speed, 122 (40, 59, 5, 18); ﬁnal visit area of intralesional MA, 4 (d, d, 0, 4).
*Vision classed as too poor to read if near VA ¼ 1.6.
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more MA with more frequent treatment have not been
replicated in our carefully conducted analysis with revised
grading deﬁnitions. We found no signiﬁcant associations of
the incidence or progression of intralesional MA over 2
years with numbers of injections (ﬁtted as treatment cycles)
or drug used. Other smaller studies have addressed this
question. Abdelfattah et al10 reported that the total number
of injections predicted the enlargement of MA in 54 eyes,
but not the development of new MA. A further study
from the same group in 88 eyes treated with ranibizumab
detected no relationship between MA development and
ﬁxed monthly dosing versus treat-and-extend regimens.11
The deﬁnitions for MA and its location were speciﬁed in
our protocol before regrading the original trial images.
Grading was conducted by trained personnel in the setting
of a large well-established reading center. We elected to
use the term intralesional MA, rather than GA, to describe
atrophy that occurred within the nAMD lesion boundaries.
The determination of MA within the boundaries of the
neovascular lesion presents a number of challenges. The
altered retinal morphologic features arising from the pres-
ence of intraretinal and subretinal ﬂuid; ﬁbrosis; and
pigment epithelial detachments, tears, or both interfered
with the visibility of choroidal vessels and the clear deter-
mination of the boundaries of atrophy both within andoutside the lesion. However, all available imaging methods,
including OCT scans, were used to identify areas of outer
retinal and RPE loss. Grading reproducibility was monitored
carefully throughout by concordance and training exercises,
and a senior grader (B.H.) reviewed all grading decisions
when intralesional MA was recorded as present at the
baseline visit and at the visit where incident intralesional
MA was detected.
We published the ﬁndings of the IVAN trial in 2015 and
reported an overall rate of incident GA in study eyes of 30%
(177/596).1 These rates were higher than in CATT, in which
187 of 1024 eyes with assessable images (18.3%)
demonstrated GA. In CATT, by removing 82 eyes which
showed GA at baseline and 79 with missing or unknown
GA status, the proportion rose to 106 of 526 eyes (20.2%).5
In both the IVAN and CATT studies, the diagnosis of GA
was based on grading of color fundus photographs (CFPs)
of any areas that ﬁtted the criteria for GA without reference
to lesion location. Eyes were classiﬁed as having GA when
CFPs showed 1 or more of these additional characteristics:
sharply demarcated borders seen in CFPs, FA, or both;
visibility of underlying choroidal vessels; excavated or
punched-out appearance on stereoscopy of CFPs or FA; or
uniform hyperﬂuorescence bounded by sharp borders on late-
phase angiography. Eligibility criteria excluded the oppor-
tunity for GA to involve the fovea in both analyses.69
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factors studied in the previous literature and in IVAN and
CATT. We identiﬁed some protective factors for the
development of atrophy within the lesion. Predominantly
classic CNV at baseline reduced the risk of development or
progression of atrophy within the lesion. This may be
because of better access to the CNV by anti-VEGF therapy;
classic or type 2 CNV typically is considered to be anterior
to the RPE. However, a greater effect on the RPE could be
seen by the drug, the lesion, or both for lesions predomi-
nately under the RPE.
The presence of SRF at the ﬁnal visit was associated with
over a halving of the odds of intralesionalMAdeveloping at the
ﬁnal visit (OR, 0.41; P ¼ 0.004). Here, SRF at ﬁnal visit is a
proxy variable for persistent SRF during the follow-up period,
suggesting that it may be protective. This ﬁnding is consistent
with those of CATT andHARBOR.12 Two secondary analyses
also support a protective effect of this proxy variable for
secondary outcomes: for incident or progressed intralesional
MA, the OR for presence of SRF at ﬁnal visit was 0.36
(P < 0.001); for total intralesional MA area, the geometric
mean ratio for presence of SRF was 0.66 (P ¼ 0.20).
Persistent SRF itself may be a protective component or
alternatively a sign that the RPE is functioning at least in part
by maintaining outer blooderetina barrier function. Sharma
at el,4 in the CATT study, reported better VA at 2 years in eyes
with SRF at the foveal center comparedwith thosewithout SRF
(72.8 letters vs. 66.6 letters; P ¼ 0.006). This protective effect
also was observed in the VEGF Trap VIEW2 study.13 The
situation with intraretinal ﬂuid is less clear. In CATT, but not
our study, the presence of intraretinal ﬂuid at 2 years was
associated with more GA (OR, 2.10) and worse VA. Like
other investigators,4 we agree that the presence of SRF alone
in the absence of intraretinal ﬂuid should not be used to
support continued aggressive treatment especially after year
1, and this includes treat-and-extend and pro re nata regimens.
In our study, the presence of PED at baseline was not
related to the development or progression of MA. This is in
contrast to the recent smaller study from the Treat-and-
Extend Age-Related Macular Degeneration Study Group
in which PED thickness at baseline was a signiﬁcant pre-
dictor of incident MA.11 However, we did detect an
association between presence of PED (deﬁned as elevation
of RPEeBruch’s membrane seen on an OCT) at the ﬁnal
visit and less intralesional MA with a similar effect size to
that seen for SRF at the ﬁnal visit. Pigment epithelial
detachments tend to indicate type 1 or predominantly sub-
RPE lesions with neovascularization ramifying within the
sub-PRE space. As suggested by other investigators,14 it
may be the case that sub-RPE neovascularization may
confer resistance to RPE atrophy, but further work is
required to investigate this.
We studied both prevalent and incident intralesional MA
in the fellow eyes of the IVAN participants, as well as study
eyes. We noted that prevalent intralesional MA was infre-
quent at baseline in fellow eyes with neovascular lesions. It
can be argued that fellow eyes with existing nAMD lesions
should have had a natural history status comparable with
that of study eyes at completion, that is, 24 months into the
trial. However, the difference was considerable, with only1018% of fellow eyes with established lesions at baseline,
almost all without exposure to anti-VEGF treatment,
exhibiting prevalent intralesional MA compared with 32%
of study eyes on study completion. This difference is sup-
ported by a lower incidence of intralesional MA observed in
fellow eyes (14% vs. 25%) over the 2-year follow-up period.
Although this comparison is not contemporaneous with the
duration of nAMD in the 2 eyes, our ﬁndings raise concerns
that prolonged exposure to anti-VEGF agents may be a risk
factor for MA.
The presence of atrophy in one eye gives useful informa-
tion on the likely future development of atrophy in the other
eye. In the study eye, intralesional MA was more likely to be
present at the ﬁnal visit if intralesional MA or GA (extrale-
sional) were present in the fellow eye at baseline (Figs 3 and
4) and if the total area of atrophy was larger (Fig S3, available
at www.aaojournal.org). A similar ﬁnding was seen in CATT
(GA in the fellow eye conferred an OR of 2.07).
Should clinicians and patients be concerned about the
effect of MA on visual function? Our ﬁndings of no sig-
niﬁcant relationship between intralesional MA and change
in BCVA, near function, or CS in the study eye provide
some reassurance. However, we did observe that changes
were in the direction of worse visual outcomes in eyes with
intralesional MA, and for near VA, the changes were close
to signiﬁcance (P ¼ 0.07). In the CATT study, VA was
worse in eyes with nongeographic atrophy and GA at 24
months, but the relationship was not investigated indepen-
dently.4 Unlike the case of morphologic measures of
atrophy, there is an inherent variability in current clinical
measures of visual function, making them less likely to
detect effects of MA. In addition, people with MA will
have developed adaptive strategies such as eccentric
viewing, rendering point measures of VA less
informative. In considering this question, we need to
emphasize the overwhelming evidence of a beneﬁcial
effect on vision of anti-VEGF therapy for nAMD. Our
OCT imaging protocol (6 radial B-scans) prevented a robust
assessment of the relationship between foveal center
involvement by MA and visual function. However, we
remain concerned that continued long-term exposure,
overexposure, or both to anti-VEGF agents may have an
adverse impact on function.
In conclusion, it is important for clinicians to recognize
that intralesional MA is common in nAMD lesions, with
approximately one third of eyes treated with anti-VEGF
drugs exhibiting this feature by 24 months. Although the
effect of intralesional MA on visual function, at least as
measured by current technology, seems to be limited, the
longer-term effects remain unknown.
Acknowledgments
We thank members of the IVAN study group listed elsewhere2 and
in the Supplemental Materials (available at www.aaojournal.org)
for their contribution to the design, collection, and interpretation
of the original IVAN trial and support for further analysis of the
dataset; the staff of the Network of Reading Centres UK in
Belfast, Liverpool, and London for grading and image analysis;
and Rebecca Evans, Clinical Trials and Evaluation Unit, Bristol,
for additional statistical analyses.
Bailey et al  Macular Atrophy in Treated Neovascular AMDReferences
1. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab
versus bevacizumab to treat neovascular age-related macular
degeneration. One-year ﬁndings from the IVAN randomized
trial. Ophthalmology. 2012;119(7):1399e1411.
2. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative
treatments to inhibit VEGF in age-related choroidal neo-
vascularisation: two-year ﬁndings of the IVAN randomised
controlled trial. Lancet. 2013:12;382(9900):1258e1267.
3. Martin DR, Maguire MG, Ying GS, et al. Ranibizumab and
bevacizumab for neovascular age-related macular degenera-
tion. N Engl J Med. 2011;364:1897e1908.
4. Sharma S, Toth CA, Daniel E, et al, for the Comparison of
Age-related Macular Degeneration Treatments Trials Research
Group. Macular morphology and visual acuity in the second
year of the Comparison of Age-related Macular Degeneration
Treatments Trials Research Group. Ophthalmology. 2016;123:
865e875.
5. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic
atrophy in the Comparison of Age-related Macular Degen-
eration Treatments Trials. Ophthalmology. 2014;121:
150e161.
6. Grunwald JE, Ebenezer D, Ying GS, the CATT Research
Group. Photographic assessment of baseline fundus morpho-
logic features in the Comparison of Age-Related Macular
Degeneration Treatments Trials. Ophthalmology. 2012;119:
1634e1641.
7. Chakravarthy U, Harding SP, Rogers CA, et al. A randomised
controlled trial to assess the clinical effectiveness andcost-effectiveness of alternative treatments to Inhibit VEGF in
Age-related choroidal Neovascularisation (IVAN). Health
Technol Assess. 2015;19(78):1e298.
8. McClure ME, Hart PM, Jackson AJ, et al. Macular degeneration:
do conventional measurements of impaired visual function equate
with visual disability? Br J Ophthalmol. 2000;84:244e250.
9. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-
related maculopathy grading system. Ophthalmology.
1991;98:1128e1134.
10. Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. Progression
of macular atrophy in patients with neovascular age-related
macular degeneration undergoing antivascular endothelial
growth factor therapy. Retina. 2016;36:1843e1850.
11. Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular
atrophy in neovascular age-related macular degeneration
with monthly versus treat-and-extend ranibizumab: ﬁndings
from the TREX-AMD trial. Ophthalmology. 2017;124:
215e223.
12. Ho AC, Busbee BG, Regillo CD, et al; for the HARBOR
Study Group. Twenty-four-month efﬁcacy and safety of 0.5
mg or 2.0 mg ranibizumab in patients with subfoveal neo-
vascular age-related macular degeneration. Ophthalmology.
2014;121:2181e2192.
13. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intra-
vitreal aﬂibercept injection for neovascular age-related macular
degeneration: ninety-six-week results of the VIEW studies.
Ophthalmology. 2014;121:193e201.
14. Dhrami-Gavazi E, Balaratnasingam C, Lee W, Freund KB.
Type 1 neovascularization may confer resistance to geographic
atrophy amongst eyes treated for neovascular age-related
macular degeneration. Int J Ret Vit. 2015;1:15.Footnotes and Financial DisclosuresOriginally received: January 5, 2018.
Final revision: July 5, 2018.
Accepted: July 13, 2018.
Available online: ---. Manuscript no. 2017-2939.
1 Bristol Eye Hospital, Bristol, United Kingdom.
2 Clinical Trials and Evaluation Unit, School of Clinical Sciences, Uni-
versity of Bristol, Bristol Royal Inﬁrmary, Bristol, United Kingdom.
3 Belfast Reading Centre, Queens University Belfast, Royal Victoria Hos-
pital, Belfast, United Kingdom.
4 Department of Ophthalmology, Queens University Belfast, Belfast,
United Kingdom.
5 Centre for Public Health, Queen’s University of Belfast, Belfast, United
Kingdom.
6 Department of Eye and Vision Science, Institute of Ageing and Chronic
Disease, University of Liverpool, Liverpool, United Kingdom.
Presented in part at: EURETINA Annual Meeting, September 2016,
Copenhagen, Denmark.
Financial Disclosure(s):
The author(s) have made the following disclosure(s): C.B.: Financial sup-
port (to institution) e Allergan, Bayer, Novartis, Alcon; Financial support
(personal): Advisory boards e Bayer, Alimera Sciences, Novartis;
Lecturer e Allergan, Bayer, Alimera Sciences, Novartis.
U.C.: Financial support (to institution) Advisory boards e Allergan, Bayer;
Lecturer e Novartis, Roche.S.P.H.: Financial support (to institution) Advisory board e Roche.
The IVAN trial was funded by the National Institute for Health Research
UK Health Technology Assessment Programme (ref: 07/36/01). The
sponsor and funding organization had no role in the design or conduct of
this research. The views and opinions expressed are those of the authors and
do not necessarily reﬂect those of the National Institute for Health Research
UK Health Technology Assessment Programme, the National Institute for
Health Research, the United Kingdom National Health Service, or the
Department of Health.
HUMAN SUBJECTS: Human subjects were included in this study. Insti-
tutional review board or ethics committee approval was obtained (identiﬁer,
07/NIR03/37), the trial was registered (identiﬁer, ISRCTN92166560), and
all participants gave informed consent. All research adhered to the tenets of
the Declaration of Helsinki.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Bailey, Rogers, Reeves, Hamill, Peto, Chakravar-
thy, Harding
Analysis and interpretation: Bailey, Scott, Rogers, Reeves, Hamill, Peto,
Chakravarthy, Harding
Data collection: Hamill, Peto, Chakravarthy, Harding
Obtained funding: Reeves, Harding, Chakravarthy
Overall responsibility: Bailey, Scott, Rogers, Reeves, Hamill, Peto, Chak-
ravarthy, Harding11
Ophthalmology Volume -, Number -, Month 2018Abbreviations and Acronyms:
BCVA ¼ best corrected visual acuity; CATT ¼ Comparison of Age-Related
Macular Degeneration Treatments Trials; CFP ¼ color fundus photograph;
CI¼ conﬁdence interval;CNV¼ choroidal neovascularization;CS¼ contrast
sensitivity; FA ¼ ﬂuorescein angiography; FPED ¼ ﬁbrovascular pigment
epithelial detachment;GA¼ geographic atrophy; IVAN¼ Inhibition of VEGF
in Age-Related Choroidal Neovascularisation; MA ¼ macular atrophy;
nAMD ¼ neovascular age-related macular degeneration; OR ¼ odds ratio;
PED ¼ pigment epithelial detachment; RPE ¼ retinal pigment epithelium;12SRF ¼ subretinal ﬂuid; VA ¼ visual acuity; VEGF ¼ vascular endothelial
growth factor.
Correspondence:
Simon P. Harding, FRCOphth, MD, Department of Eye and Vision Sci-
ence, Institute of Ageing and Chronic Disease, University of Liverpool,
William Duncan Building, West Derby Street, Liverpool, United Kingdom.
E-mail: s.p.harding@liv.ac.uk.
